These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34335822)

  • 41. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.
    Li Y; Jing Q; Wang B; Wang X; Li J; Qiao S; Chen S; Angiolillo DJ; Han Y
    Am Heart J; 2020 Oct; 228():1-7. PubMed ID: 32739652
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
    Helft G; Le Feuvre C; Georges JL; Carrie D; Leclercq F; Eltchaninoff H; Furber A; Prunier F; Sebagh L; Cattan S; Cayla G; Vicaut E; Metzger JP
    Trials; 2013 Feb; 14():56. PubMed ID: 23433461
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors.
    Coccheri S
    Drugs; 2010 May; 70(7):887-908. PubMed ID: 20426498
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Panax notoginseng saponins on the pharmacokinetics of aspirin in rats.
    Tian Z; Pang H; Du S; Lu Y; Zhang L; Wu H; Guo S; Wang M; Zhang Q
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jan; 1040():136-143. PubMed ID: 27978468
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects.
    Traby L; Kollars M; Kaider A; Eichinger S; Wolzt M; Kyrle PA
    J Thromb Haemost; 2016 Feb; 14(2):273-81. PubMed ID: 26663880
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
    De Schryver EL; Algra A; van Gijn J
    Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial.
    Johnson TW; Baos S; Collett L; Hutchinson JL; Nkau M; Molina M; Aungraheeta R; Reilly-Stitt C; Bowles R; Reeves BC; Rogers CA; Mundell SJ; Baumbach A; Mumford AD
    J Am Heart Assoc; 2020 Dec; 9(24):e016495. PubMed ID: 33305660
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: a randomized controlled trial.
    Ren Y; Cao SL; Li Z; Luo T; Feng B; Weng XS
    Chin Med J (Engl); 2021 Jan; 134(2):164-172. PubMed ID: 33410616
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
    Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
    Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N
    Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
    Saito Y; Okada S; Ogawa H; Soejima H; Sakuma M; Nakayama M; Doi N; Jinnouchi H; Waki M; Masuda I; Morimoto T;
    Circulation; 2017 Feb; 135(7):659-670. PubMed ID: 27881565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
    Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW;
    JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial.
    Lee S; Lee HY; Park KW; Kang HJ; Koo BK; Kim HS; Choi DJ; Kim MA; Oh BH
    Am J Cardiovasc Drugs; 2013 Dec; 13(6):413-24. PubMed ID: 23913405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Hoshi T; Sato A; Nogami A; Gosho M; Aonuma K;
    J Cardiol; 2017 Apr; 69(4):648-651. PubMed ID: 27443596
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized, double-blind, placebo- controlled study on the anti-haemostatic effects of Curcuma longa, Angelica sinensis and Panax ginseng.
    Fung FY; Wong WH; Ang SK; Koh HL; Kun MC; Lee LH; Li X; Ng HJ; Tan CW; Zhao Y; Linn YC
    Phytomedicine; 2017 Aug; 32():88-96. PubMed ID: 28732813
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
    Song YB; Oh SK; Oh JH; Im ES; Cho DK; Cho BR; Lee JY; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY
    Am Heart J; 2018 Mar; 197():77-84. PubMed ID: 29447787
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An App-Based Intervention for Caregivers to Prevent Unintentional Injury Among Preschoolers: Cluster Randomized Controlled Trial.
    Ning P; Cheng P; Schwebel DC; Yang Y; Yu R; Deng J; Li S; Hu G
    JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13519. PubMed ID: 31400105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.